28.70
price down icon1.27%   -0.37
after-market After Hours: 28.72 0.02 +0.07%
loading
Royalty Pharma Plc stock is traded at $28.70, with a volume of 1.86M. It is down -1.27% in the last 24 hours and up +5.90% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$29.07
Open:
$29.03
24h Volume:
1.86M
Relative Volume:
0.77
Market Cap:
$12.86B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
255.11
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
-1.14%
1M Performance:
+5.90%
6M Performance:
-3.50%
1Y Performance:
-1.27%
1-Day Range:
Value
$28.61
$29.12
1-Week Range:
Value
$28.61
$29.36
52-Week Range:
Value
$25.20
$31.66

Royalty Pharma Plc Stock (RPRX) Company Profile

Name
Name
Royalty Pharma Plc
Name
Phone
(212) 883-0200
Name
Address
110 EAST 59TH STREET, NEW YORK, NY
Name
Employee
89
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
RPRX's Discussions on Twitter

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-03-24 Downgrade UBS Buy → Neutral
Jun-14-22 Resumed UBS Buy
May-13-22 Initiated Scotiabank Sector Outperform
Apr-27-22 Initiated Goldman Buy
Apr-14-22 Upgrade JP Morgan Neutral → Overweight
Apr-06-22 Resumed Morgan Stanley Overweight
Oct-29-21 Upgrade Citigroup Neutral → Buy
Jul-30-21 Initiated Tigress Financial Buy
Nov-09-20 Upgrade UBS Neutral → Buy
Jul-14-20 Initiated Evercore ISI In-line
Jul-13-20 Initiated BofA Securities Buy
Jul-13-20 Initiated Citigroup Neutral
Jul-13-20 Initiated Cowen Outperform
Jul-13-20 Initiated Goldman Neutral
Jul-13-20 Initiated JP Morgan Neutral
Jul-13-20 Initiated Morgan Stanley Equal-Weight
Jul-13-20 Initiated SunTrust Buy
Jul-13-20 Initiated UBS Neutral
View All

Royalty Pharma Plc Stock (RPRX) Latest News

pulisher
Sep 08, 2024

New South Capital Management Inc. Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Sep 08, 2024
pulisher
Sep 07, 2024

Torray Investment Partners LLC Boosts Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Sep 07, 2024
pulisher
Sep 06, 2024

Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - Yahoo Finance

Sep 06, 2024
pulisher
Sep 05, 2024

143,912 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Hohimer Wealth Management LLC - MarketBeat

Sep 05, 2024
pulisher
Sep 04, 2024

Watkins Advises Ascendis Pharma in US$150 Million Royalty Financing - Latham & Watkins LLP -

Sep 04, 2024
pulisher
Sep 04, 2024

Regal Partners Ltd Purchases 217,774 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

Ascendis Pharma secures $150 million royalty deal for YORVIPATH By Investing.com - Investing.com Australia

Sep 04, 2024
pulisher
Sep 03, 2024

Ascendis Pharma secures $150 million royalty deal for YORVIPATH - Investing.com India

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma secures $150 million royalty deal for YORVIPATH By Investing.com - Investing.com Canada

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma secures $150 million royalty deal for YORVIPATH By Investing.com - Investing.com UK

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma, Royalty Pharma enter $150M royalty funding deal - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement - StockTitan

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - The Bakersfield Californian

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - StockTitan

Sep 03, 2024
pulisher
Sep 03, 2024

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - Yahoo Finance UK

Sep 03, 2024
pulisher
Sep 02, 2024

Bank of New York Mellon Corp Purchases 86,248 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Sep 02, 2024
pulisher
Sep 01, 2024

Panagora Asset Management Inc. Sells 129,378 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Sep 01, 2024
pulisher
Aug 31, 2024

Searle & CO. Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Aug 31, 2024
pulisher
Aug 30, 2024

Royalty Pharma (NASDAQ:RPRX) Lifted to Buy at StockNews.com - MarketBeat

Aug 30, 2024
pulisher
Aug 29, 2024

Royalty Pharma plc (RPRX) is looking forward to a strong quarter - SETE News

Aug 29, 2024
pulisher
Aug 28, 2024

Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference - StockTitan

Aug 28, 2024
pulisher
Aug 28, 2024

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt - Simply Wall St

Aug 28, 2024
pulisher
Aug 26, 2024

(RPRX) On The My Stocks Page - Stock Traders Daily

Aug 26, 2024
pulisher
Aug 26, 2024

Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’ - Yahoo Finance UK

Aug 26, 2024
pulisher
Aug 26, 2024

Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’ - Insider Monkey

Aug 26, 2024
pulisher
Aug 26, 2024

Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’ - Yahoo Finance

Aug 26, 2024
pulisher
Aug 25, 2024

Royalty Pharma (NASDAQ:RPRX) Sees Strong Trading Volume - Defense World

Aug 25, 2024
pulisher
Aug 25, 2024

Overbrook Management Corp Reduces Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Aug 25, 2024
pulisher
Aug 25, 2024

Envestnet Portfolio Solutions Inc. Acquires Shares of 9,616 Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Aug 25, 2024
pulisher
Aug 25, 2024

SG Americas Securities LLC Sells 88,380 Shares of Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Aug 25, 2024
pulisher
Aug 24, 2024

Envestnet Portfolio Solutions Inc. Invests $254,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Aug 24, 2024
pulisher
Aug 23, 2024

Royalty Pharma (NASDAQ:RPRX) Lowered to Hold at StockNews.com - Defense World

Aug 23, 2024
pulisher
Aug 23, 2024

Raymond James & Associates Has $19.35 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Aug 23, 2024
pulisher
Aug 23, 2024

Raymond James & Associates Has $19.35 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Aug 23, 2024
pulisher
Aug 23, 2024

Jim Cramer’s Latest Lightning Round: Top 10 Stocks - Insider Monkey

Aug 23, 2024
pulisher
Aug 22, 2024

StockNews.com Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold - MarketBeat

Aug 22, 2024
pulisher
Aug 22, 2024

Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading Volume - MarketBeat

Aug 22, 2024
pulisher
Aug 22, 2024

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating (NASDAQ:RPRX) - Seeking Alpha

Aug 22, 2024
pulisher
Aug 20, 2024

Sumitomo Mitsui Trust Holdings Inc. Buys 62,218 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Aug 20, 2024
pulisher
Aug 20, 2024

Sumitomo Mitsui Trust Holdings Inc. Has $26.20 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Aug 20, 2024
pulisher
Aug 17, 2024

Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? - Insider Monkey

Aug 17, 2024
pulisher
Aug 17, 2024

Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now? - Yahoo Finance

Aug 17, 2024
pulisher
Aug 16, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Swedbank AB - MarketBeat

Aug 16, 2024
pulisher
Aug 16, 2024

10 Best Defensive Stocks To Buy Now - Insider Monkey

Aug 16, 2024
pulisher
Aug 16, 2024

First Week of April 2025 Options Trading For Royalty Pharma (RPRX) - Nasdaq

Aug 16, 2024
pulisher
Aug 16, 2024

The Goldman Sachs Group Increases Royalty Pharma (NASDAQ:RPRX) Price Target to $51.00 - Defense World

Aug 16, 2024
pulisher
Aug 16, 2024

Cwm LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Aug 16, 2024
pulisher
Aug 15, 2024

Royalty Pharma plc (NASDAQ:RPRX) Announces Quarterly Dividend of $0.21 - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Royalty Pharma plc (NASDAQ:RPRX) Receives $42.00 Average Price Target from Brokerages - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

Royalty Pharma plc (NASDAQ:RPRX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Aug 15, 2024

Royalty Pharma Plc Stock (RPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Royalty Pharma Plc Stock (RPRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
RIGGS RORY B
Director
Jan 02 '24
Sale
28.52
235,200
6,707,081
254,899
RIGGS RORY B
Director
Jan 03 '24
Sale
27.79
199,098
5,532,276
55,801
RIGGS RORY B
Director
Jan 04 '24
Sale
27.55
35,702
983,504
20,099
Avara Management Ltd
10% Owner
Dec 29 '23
Sale
28.04
65,803
1,845,406
2,477,520
Avara Management Ltd
10% Owner
Dec 28 '23
Sale
28.20
209,863
5,918,934
2,543,323
Avara Management Ltd
10% Owner
Dec 27 '23
Sale
28.01
41,729
1,168,754
2,753,186
Avara Management Ltd
10% Owner
Dec 15 '23
Sale
28.01
10,229
286,499
2,794,915
Avara Management Ltd
10% Owner
Dec 14 '23
Sale
28.91
364,441
10,534,276
2,805,144
Avara Management Ltd
10% Owner
Dec 13 '23
Sale
28.95
307,935
8,916,012
3,169,585
$84.08
price down icon 1.22%
$27.52
price down icon 0.61%
$191.32
price down icon 0.14%
$89.94
price down icon 0.23%
$72.89
price down icon 0.75%
$246.78
price down icon 1.87%
Cap:     |  Volume (24h):